Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etanercept + DMARDs
- Development stage
- Unknown
- Lead developer
- TSH Biopharm
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
ENIA11 (brand name TuNEX) is a biosimilar of etanercept, a recombinant fusion protein that functions as a soluble tumor necrosis factor (TNF) receptor. Developed by Mycenax Biotech and TSH Biopharm, ENIA11 consists of the extracellular ligand-binding portion of the human 75 kDa (p75) TNF receptor linked to the Fc portion of human IgG1. It works by binding to TNF-alpha and TNF-beta, thereby preventing their interaction with cell surface TNF receptors and inhibiting the downstream inflammatory cascade. In clinical practice, ENIA11 is often administered in combination with conventional synthetic disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, to treat patients with rheumatoid arthritis who have had an inadequate response to DMARD monotherapy. This combination approach aims to achieve better disease control and improve clinical outcomes in inflammatory conditions like rheumatoid arthritis and ankylosing spondylitis.
- Brand names
- TuNEX
- Other names
- ENIA11 + DMARDsTuNEX + DMARDsetanercept biosimilar + DMARDs
02
Targets
DHFR (Dihydrofolate reductase)TNFA (Tumor necrosis factor alpha (soluble))TNFR2 (Tumor necrosis factor receptor superfamily member 1B)
Beyond the preview
Go deeper on etanercept + DMARDs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etanercept + DMARDs.